Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer
Author:
Funder
National Center Institute
CPRIT
Publisher
American Society for Clinical Investigation
Subject
General Medicine
Link
https://www.jci.org/articles/view/160330/files/pdf
Reference41 articles.
1. FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets
2. EGFR Mutations and Lung Cancer
3. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
4. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Role of Serine Protease 8 in Mediating Gefitinib Resistance in Non-small Cell Lung Cancer;Anti-Cancer Agents in Medicinal Chemistry;2024-11
2. Exploring the multifaceted role of direct interaction between cancer cells and fibroblasts in cancer progression;Frontiers in Molecular Biosciences;2024-05-28
3. Identifying the cancer-associated fibroblast signature to predict the prognosis and immunotherapy response in patients with lung squamous cell carcinoma;Computer Methods in Biomechanics and Biomedical Engineering;2023-11-28
4. Fused multimodal radiomics with deep learning for predicting EGFR-sensitizing mutations based on 18F- PET/CT images;2023 IEEE Nuclear Science Symposium, Medical Imaging Conference and International Symposium on Room-Temperature Semiconductor Detectors (NSS MIC RTSD);2023-11-04
5. Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8+T cell infiltration and functional transition;Journal for ImmunoTherapy of Cancer;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3